Skip navigation
Back to STV Home
Technology Information
Title
Dopaminergic cell lines stably expressing A53T Alpha-Synuclein and methods of using same
Case Number
1320
Abstract
Name of the inventor: Leonidas Stefanis and Lloyd Greene
The invention discloses a PC12 cell line stably expressing Human A53Talpha-synuclein, and methods of using the same. The cells of the cell line are characterized by proteasomal dysfunction, dopaminergic dysfunction, lysosomal dysfunction, and increased non-apoptotic cell death.
A method for generating a dopaminergic cell line involves introducing an expression vector into a population of rat PC12 cells, where the expression vector is under the control of a promoter. The PC12 cell lines stably expressing human A53Talpha-synuclein is then isolated. Dysfunction is determined by the increased presence of the isolated cell line, as compared to a cell from a suitable control cell line not expressing mutant alpha-synuclein.
The method provides a cellular model for the study of Parkinson's disease, and other neurodegenerative disorders like Dementia, Alzheimer's disease, Multiple System Atrophy and Hallervorden-Spatz syndrome.
Taxonomy
Therapeutic/Healthcare
Cell Line/Research Tool
Expression System/Research Tool
Disease Model/Therapeutic
Keywords
Alzheimer's Disease, Parkinson's Disease, Human A53T , alpha.-synuclein, cell lines, expression vector, PC12 cells, Lewy bodies, pheochromocytoma, neomycin, dysfunction, proteasomal
Licensing Contact
The responsible technology licensing officer is Jerry Kokoshka but for more information on this technology, please contact
stvinfo@columbia.edu
.
Web Links
Name
Description
Open Link
Patent number: US20040197315
Click Here
Request Information
If you are a registered user, please login before requesting information by clicking the Login button. If you have not registered, click the Login button for registration information.
